These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17121896)

  • 1. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.
    Cusack JC; Liu R; Xia L; Chao TH; Pien C; Niu W; Palombella VJ; Neuteboom ST; Palladino MA
    Clin Cancer Res; 2006 Nov; 12(22):6758-64. PubMed ID: 17121896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
    Chauhan D; Catley L; Li G; Podar K; Hideshima T; Velankar M; Mitsiades C; Mitsiades N; Yasui H; Letai A; Ovaa H; Berkers C; Nicholson B; Chao TH; Neuteboom ST; Richardson P; Palladino MA; Anderson KC
    Cancer Cell; 2005 Nov; 8(5):407-19. PubMed ID: 16286248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
    Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
    Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
    Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
    Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
    Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
    An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
    Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
    Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
    J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
    Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
    Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of miconazole on human colon carcinoma xenografts in nude mice through induction of apoptosis and G0/G1 cell cycle arrest.
    Wu CH; Jeng JH; Wang YJ; Tseng CJ; Liang YC; Chen CH; Lee HM; Lin JK; Lin CH; Lin SY; Li CP; Ho YS
    Toxicol Appl Pharmacol; 2002 Apr; 180(1):22-35. PubMed ID: 11922774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
    Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
    Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitizing properties of bortezomib depend on therapeutic schedule.
    Labussière M; Pinel S; Vandamme M; Plénat F; Chastagner P
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):892-900. PubMed ID: 21168283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor.
    Macherla VR; Mitchell SS; Manam RR; Reed KA; Chao TH; Nicholson B; Deyanat-Yazdi G; Mai B; Jensen PR; Fenical WF; Neuteboom ST; Lam KS; Palladino MA; Potts BC
    J Med Chem; 2005 Jun; 48(11):3684-7. PubMed ID: 15916417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
    Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
    Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization.
    Baritaki S; Yeung K; Palladino M; Berenson J; Bonavida B
    Cancer Res; 2009 Nov; 69(21):8376-85. PubMed ID: 19843864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice.
    Golab J; Stoklosa T; Czajka A; Dabrowska A; Jakobisiak M; Zagozdzon R; Wojcik C; Marczak M; Wilk S
    Anticancer Res; 2000; 20(3A):1717-21. PubMed ID: 10928098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo.
    Zhang C; Wu R; Zhu H; Hu YZ; Jiang H; Lin NM; He QJ; Yang B
    Cancer Lett; 2011 Mar; 302(1):11-9. PubMed ID: 21236562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
    Adachi M; Zhang Y; Zhao X; Minami T; Kawamura R; Hinoda Y; Imai K
    Clin Cancer Res; 2004 Jun; 10(11):3853-62. PubMed ID: 15173094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.